Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

MicroPort®

MicroPort Scientific Corporation

微創醫療科學有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 00853)

ESTIMATED ANNUAL RESULTS OF SHANGHAI MICROPORT ENDOVASCULAR MEDTECH (GROUP) CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2024

The board of directors (the "**Board**") of MicroPort Scientific Corporation (the "**Company**", together with its subsidiaries, the "**Group**") wishes to inform shareholders and potential investors of the Company that, based on the information currently available to the management of the Company, the revenue of Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. ("**EV MedTech**") for the year ended 31 December 2024 (the "**Reporting Period**") is expected to be between RMB1,187.5 million and RMB1,306.0 million, representing an increase of between 0.02% and 10.01% as compared with 2023; the net profit attributable to equity owners of EV MedTech for the Reporting Period is expected to be between RMB492.5 million and RMB541.0 million, representing an increase of between 0.01% and 9.86% as compared with 2023.

During the Reporting Period, the innovative products of EV MedTech, including Castor® Branched Aortic Stent Graft and Delivery System, Minos® Abdominal Aortic Stent Graft and Delivery System and Reewarm® PTX Drug Balloon Dilatation Catheter, continued to contribute momentum, in the meantime the numbers of hospitals entered and terminal implants for the new products of EV MedTech, including Talos® Thoracic Stent Graft System and Fontus® Branched Surgical Stent Graft System, grew rapidly. However, the annual sales growth rate and profit were affected having regard to factors including the changes in the market environment and the adjustments made by EV MedTech to its product pricing and marketing strategies in the second half of the year.

In terms of markets, EV MedTech continued to develop China's municipal and county hospitals while continuing to step up its marketing efforts overseas, with its overseas revenue exceeding RMB150 million and the proportion of overseas revenue increasing further during the Reporting Period.

EV MedTech is owned as to 40.32% by the Group and its results are consolidated into the financial statements of the Company. The shares of EV MedTech are listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange.

Shareholders and investors are reminded that the financial information of EV MedTech above was prepared in accordance with PRC accounting standards and are limited solely to the operation of EV MedTech and are unrelated to the other subsidiaries of the Group. Such information is unaudited and has not been reviewed by the auditors or the audit committee of the Company and does not (a) exclude intra-group transactions, (b) include all the business of the Group, and (c) represent or provide a full picture of the operation or status of the Group. **Shareholders and potential investors of the Company are reminded to exercise caution when dealing in the securities of the Company.**

By order of the Board
MicroPort Scientific Corporation
Dr. Zhaohua Chang
Chairman

Shanghai, the PRC, 20 January 2025

As at the date of this announcement, the executive director of the Company is Dr. Zhaohua Chang; the non-executive directors of the Company are Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida and Ms. Weiqin Sun; and the independent nonexecutive directors of the Company are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.

* *For identification purposes only*